Comparison of three enzyme-linked immunosorbent assays and a direct fluorescent-antibody test for detection of respiratory syncytial virus antigen.

1988 ◽  
Vol 26 (2) ◽  
pp. 377-379 ◽  
Author(s):  
L R Krilov ◽  
L Marcoux ◽  
H D Isenberg
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fluorescent Antibody ◽  
Antibody Test ◽  
Virus Antigen ◽  
Direct Fluorescent Antibody ◽  
Respiratory Syncytial Virus Antigen ◽  
Immunosorbent Assays ◽  
Syncytial Virus

A study of possible biohazards in the fluorescent antibody test using adenovirus, coxsackievirus, herpesvirus, and respiratory syncytial virus as antigens

1976 ◽  
Vol 4 (4) ◽  
pp. 322-325
Author(s):  
D Bardell
Keyword(s):  
Respiratory Syncytial Virus ◽  
Infectious Virus ◽  
Fluorescent Antibody ◽  
Antibody Test ◽  
Adenovirus Type ◽  
Antigenic Determinants ◽  
Syncytial Virus ◽  
Simplex Virus ◽  
Adenovirus Type 5

Infectious adenovirus type 5 and coxsackievirus type B5, both nonlipid-containing viruses, were isolated from cells fixed in acetone at 22 degrees C for 15 min, from acetone used for fixation, from the solution used for washing slides during the fluorescent antibody procedure, and after complete processing of antigen preparations with serial twofold dilutions of human antisera and fluorescein-labeled goat anti-human immunoglobulin G. Lipid-containing herpes simplex virus type 1 and respiratory syncytial virus were inactivated by acetone, and infectious virus could not be recovered at any stage in the fluorescent antibody test. Fixation in acetone at 56 degrees C destroyed the infectivity of adenovirus 5 and coxsackievirus B5 within 30 min, but no adverse effect on the antigenic determinants of either virus occurred until after 60 min, thus demonstrating that these antigens can be utilized without the hazard of infectious virus.

Efficacy of Ribavirin Aerosol Treatment for Respiratory Syncytial Virus Bronchiolitis in Infants

1987 ◽  
Vol 15 (4) ◽  
pp. 227-233 ◽  
Author(s):  
G. Caramia ◽  
E. Palazzini
Keyword(s):  
Respiratory Syncytial Virus ◽  
Body Temperature ◽  
Marked Improvement ◽  
Virus Antigen ◽  
The Body ◽  
Viral Agent ◽  
Nasal Wash ◽  
Respiratory Syncytial Virus Antigen ◽  
Syncytial Virus ◽  
Therapeutic Selectivity

The therapeutic efficacy of ribavirin, an anti-viral agent with a broad spectrum of activity, was studied in 14 infants with bronchiolitis which, in seven cases, was caused by a respiratory syncytial virus infection. The drug was administered for 5–6 days using an aerosol in periods of either 4 or 6 h with an interval of either 4 or 2 h between administrations. The body temperature of patients with fever returned to normal by day 3 of therapy. A significant decrease in the respiratory rate occurred by day 2 when there was also a marked improvement in the subjective and objective symptomatology. The most significant clinical improvements occurred in infants presenting a respiratory syncytial virus antigen in nasal wash specimens. This suggests therapeutic selectivity by ribavirin for (or a more pronounced sensibility of) this virus.

Sign in / Sign up

Export Citation Format

Share Document